# A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)

> **NCT02576665** · PHASE1 · TERMINATED · sponsor: **Tocagen Inc.** · enrollment: 21 (actual)

## Conditions studied

- Colorectal Cancer
- Triple Negative Breast Cancer
- Pancreatic Cancer
- Non-Small Cell Lung Cancer
- Head and Neck Cancer
- Ovarian Cancer
- Lymphoma
- Sarcoma
- Bladder Cancer
- Melanoma
- IDH1 Mutated Solid Tumors
- IDH1 Mutated or MGMT Methylated Recurrent HGG (Not Recruiting)

## Interventions

- **BIOLOGICAL:** Toca 511
- **DRUG:** Toca FC

## Key facts

- **NCT ID:** NCT02576665
- **Lead sponsor:** Tocagen Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-07
- **Primary completion:** 2019-05
- **Final completion:** 2019-12-20
- **Target enrollment:** 21 (ACTUAL)
- **Why stopped:** Sponsor decision
- **Last updated:** 2020-02-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02576665

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02576665, "A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02576665. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*